TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18489634
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oxycodone/650 mg acetaminophen
Study: 18489634
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hydrocodone/650 mg acetaminophen
Study: 18489634
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hydrocodone/325 mg acetaminophen
Study: 8690107
Drug: GH‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH‐releasing hormone (GH‐RH) (1 mg/kg body weight)
Study: 8690107
Drug: Pyridostigmine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (120 mg by mouth)
Study: 8690107
Drug: Arginine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine (30 g infused IV over a 30‐minute period)
Study: 8690107
Drug: Insulin growth
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin growth factor‐I levels
Study: 29171557
Drug: Supervised structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised structured aerobic exercise training programme, routine medication and dietary plan for 25 weeks at 3 days per week
Study: 15754699
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with oral laxative (lactulose 66.7%), metronidazole, and topical glyceryl-trinitrate ointment at 0.2% pre and postoperative
Study: 11600528
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release recombinant human GH at 1.5 mg/kg once monthly
Study: 11600528
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release recombinant human GH at 0.75 mg/kg twice monthly
Study: 2213286
Drug: Thiazide with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide with potassium-sparing agent
Study: 2213286
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive agents
Study: 44015
Drug: Thioproperazine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioproperazine (3 x 3 mg/day)
Study: 44015
Drug: Tiapride (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride (3 x 100 mg/day)
Study: 31605208
Drug: Mineral water
Normalized name: mineral water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral water baths (20 g/L)
Study: 31605208
Drug: Mineral water
Normalized name: mineral water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral water baths (40 g/L)
Study: 31605208
Drug: Mineral water
Normalized name: mineral water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral water baths (60 g/L)
Study: 31327147
Drug: 0.5% Carbomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Carbomer 980 Gel
Study: 27522605
Drug: Seabuckthorn seed
Normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seabuckthorn seed oil at a daily dose of 0.75 ml for 30 days
Study: 24469972
Drug: 300,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300,000 IU intramuscular cholecalciferol
Study: 24469972
Drug: 25,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25,000 IU oral cholecalciferol monthly
Study: 22930004
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (triptorelin 0.2 mg) followed by 1500 IU hCG 35 h after triggering final oocyte maturation and standard luteal phase support (Protocol B)
Study: 22930004
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (triptorelin 0.2 mg) and standard luteal phase support (Protocol C)
Study: 22930004
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (triptorelin 0.2 mg) without luteal phase support (Protocol D)
Study: 10597869
Drug: Ebastine 10mg
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10mg once daily for 2 to 3 weeks
Study: 10597869
Drug: Ebastine 20mg
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 20mg once daily for 2 to 3 weeks
Study: 10597869
Drug: Ebastine 10mg
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10mg twice daily for 3 weeks
Study: 10597869
Drug: Ebastine 20mg
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 20mg once daily for 3 weeks
Study: 7703058
Drug: Vein patch
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein patch closure
Study: 23549516
Drug: Metipranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metipranolol (10 mg twice per day)
Study: 23405020
Drug: Preoperative physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative physical therapy (respiratory and global exercises) for 2-3 weeks before surgery
Study: 23405020
Drug: Preoperative physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative physical therapy
Study: 23405020
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (preoperative physical therapy)
Study: 21989099
Drug: Weight monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight monitoring and recording (measured, recorded, and announced twice a week for 3 months)
Study: 18829219
Drug: Balneotherapy associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneotherapy associated with patient education (spa treatment course in La Léchère) consisting of four balneology sessions per day, six days a week for three weeks, and three educational workshops.
Study: 18829219
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received spa treatment starting at day 365 (after the treatment group).
Study: 9218070
Drug: Regular coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular coffee (300 mL)
Study: 9218070
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (300 mL)
Study: 8525856
Drug: Overall group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall group (Moclobemide and Sertraline)
Study: 2492322
Drug: Continuous nitroglycerin
Normalized name: nitroglycerin Extended Release Oral Tablet [Nitrocontin Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nitroglycerin patches (10 mg/day)
Study: 2492322
Drug: Intermittent nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nitroglycerin patches (10 mg/day) for 18 h/day with 6 h off
Study: 2492322
Drug: Intermittent nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nitroglycerin patches (10 mg/day) for 14 h/day with 10 h off
Study: 2492322
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment (10 h off)
Study: 30924702
Drug: SPN-812 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-812 300 mg/day
Study: 30924702
Drug: SPN-812 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-812 400 mg/day
Study: 25227967
Drug: Initial high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial high-dose prednisolone combination therapy using COBRA regimen (methotrexate and sulfasalazine)
Study: 25227967
Drug: COBRA-light variation
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA-light variation of COBRA combination therapy
Study: 25227967
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate and infliximab combination therapy
Study: 21777013
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg/day, uptitrated to 40 mg/day or combined with HCTZ 40/12.5 mg/day or 40/25 mg/day
Study: 11207321
Drug: IC14 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC14 (1 mg/kg over 1 h)
Study: 3129273
Drug: Combined insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined insulin and glibenclamide (Euglucon N)
Study: 3129273
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (placebo)
Study: 29795403
Drug: 2-mg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg dose of nicotine
Study: 27988164
Drug: Single-dose interscalene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose interscalene block and general anesthesia (SISB/GA)
Study: 21041606
Drug: Fluoxetine hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride treatment
Study: 21041606
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluoxetine and cognitive behavioral therapy
Study: 9412795
Drug: Triptorelin (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (3.75 mg i.m.)
Study: 16359772
Drug: Leuprolin (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolin (3.75 mg i.m.)
Study: 14521759
Drug: IL-2 +
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 + 3PaZ(TH)L(2)VE(AK) + 4PaL(2)V
Study: 14521759
Drug: 3PaZ(TH)L(2)VE(AK)/4PaL(2)V
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3PaZ(TH)L(2)VE(AK)/4PaL(2)V
Study: 8799270
Drug: Gas chromatography/combustion/carbon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gas chromatography/combustion/carbon isotope ratio mass spectrometry (GC/C/IRMS) analysis of urinary steroids
Study: 1361356
Drug: Vecuronium (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.08 mg kg‐1)
Study: 26586300
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field therapy (PEMF) applied to one side of the face post-surgery.
Study: 23008295
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate
Study: 19952863
Drug: HPV‐6/11/16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV‐6/11/16/18 vaccine
Study: 17636242
Drug: Vaginal suppositories
Normalized name: Miconazole Nitrate Vaginal Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppositories containing 2.5 mg bromocriptine mesthylate with pluronics and bioadhesive agents, once daily for 1 month
Study: 17636242
Drug: Commercial 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial 2.5 mg bromocriptine mesthylate tablets inserted vaginally, once daily for 1 month
Study: 12146001
Drug: Exemestane 10
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane 10 mg/day
Study: 12146001
Drug: Total group
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total group (10 mg + 25 mg)
Study: 10413640
Drug: Efegatran at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efegatran at 1.2 mg. kg(‐1). h(‐1)
Study: 10413640
Drug: Efegatran (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efegatran (various doses)
Study: 10413640
Drug: Efegatran at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efegatran at levels of at least 0.63 mg. kg(‐1). h(‐1)
Study: 7768238
Drug: 6.9% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.9% CHO solution
Study: 7768238
Drug: 5.5% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.5% CHO solution
Study: 7306430
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg three times daily and 400 mg at night for 6 days
Study: 19203712
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (0, 15 or 30 mg Zn per day for 6 months)
Study: 19203712
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 mg Zn per day for 6 months)
Study: 11855146
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) in combination with corticosteroid (prednisone + danazol)
Study: 9771080
Drug: Latanoprost (0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost (0.005% xalathane solution)
Study: 9771080
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of latanoprost with pilocarpine + timolol
Study: 7930743
Drug: Artesunate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (10 mg/kg over 3 days) plus mefloquine (25 mg/kg)
Study: 7930743
Drug: High-dose mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose mefloquine alone
Study: 7930743
Drug: Mefloquine on
Normalized name: Mefloquine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine on day 2 of treatment
Study: 22428914
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Glucobay® 100 mg tablet)
Study: 22428914
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (generic acarbose 100 mg tablet)
Study: 12722964
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 microg daily
Study: 8469785
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 400 mg three times daily for 12 weeks
Study: 26850676
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (orally inhaled salbutamol)
Study: 26850676
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (orally inhaled salbutamol)
Study: 22382087
Drug: Integral doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integral doses
Study: 21102969
Drug: OM-ER 15
Normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OM-ER 15 mg
Study: 21102969
Drug: OM-ER 30
Normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OM-ER 30 mg
Study: 10224679
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy laser radiation treatment in addition to routine antibiotic therapy
Study: 10224679
Drug: Routine antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antibiotic therapy
Study: 2004544
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 125 mg twice daily
Study: 24067745
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (200 ml, three times daily for 3 days)
Study: 23469595
Drug: Shuangshen Tongguan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuangshen Tongguan Capsule (STC), 4 pills each time, three times daily
Study: 30944162
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of peroral metronidazole/amoxicillin antibiotic treatment
Study: 7168635
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic treatment (control group)
Study: 8756815
Drug: Placebo (excipient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (excipient only) inhalation
Study: 2017519
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment (chronic)
Study: 31068182
Drug: Normal platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal platelet counts (≥150 to <300 × 10^9/L)
Study: 27857631
Drug: Passive soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive soft tissue therapy
Study: 27857631
Drug: Active soft
Normalized name: Nature's Way Petadolex Pro-Active Softgels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active soft tissue therapy
Study: 20965712
Drug: Beclomethasone/formoterol (200/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone/formoterol (200/12 μg)
Study: 20965712
Drug: Budesonide/formoterol (400/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (400/12 μg)
Study: 20965712
Drug: Formoterol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (12 μg)
Study: 28469157
Drug: Deferiprone 10
Normalized name: deferiprone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone 10 mg/kg BID
Study: 28469157
Drug: Deferiprone 15
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone 15 mg/kg BID
Study: 28469157
Drug: Deferiprone 30
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone 30 mg/kg
Study: 12037450
Drug: Calcipotriol ointment/scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment/scalp solution (80-100 g/week and 30-50 ml/week, respectively)
Study: 139852
Drug: Metronidazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (400 mg three times daily for 10-20 days)
Study: 17584567
Drug: Thiazolidinedione therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazolidinedione therapy (pioglitazone or rosiglitazone)
Study: 15089940
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide suspension [Ca(OH)2]
Study: 11294429
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs post-operatively for 3-6 weeks
Study: 9257419
Drug: Spreadsheet method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spreadsheet method for displaying drug dosing histories
Study: 8177603
Drug: Sclero cryo
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclero cryo therapy
Study: 29320587
Drug: Basic skin
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic skin care regimen following hyaluronic acid filler and neurotoxin treatment
Study: 29320587
Drug: Nu‐Derm® skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nu‐Derm® skin care system (Obagi Medical Products, Inc) following treatment
Study: 27097354
Drug: Low-dose albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose albumin plus terlipressin
Study: 21309374
Drug: Sensory Integration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory Integration (SI) treatment group
Study: 21309374
Drug: Fine motor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fine motor treatment group
Study: 15080821
Drug: Desloratadine (DES)
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine (DES) 5 mg
Study: 15151516
Drug: Fexofenadine (FEX)
Normalized name: fexofenadine Oral Tablet [Wal-Fex]
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine (FEX) 180 mg
Study: 15080821
Drug: Levocetirizine (LEV)
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine (LEV) 5 mg
Study: 11280457
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg azithromycin once a day for four days per month along with 0.05% topical tretinoin for a total of 12 weeks
Study: 11280457
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg doxycycline daily in addition to topical 0.05% tretinoin cream for a total of 12 weeks
Study: 8504628
Drug: Intravenous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous low dose aspirin (50 mg)
Study: 8504628
Drug: Intravenous high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous high dose aspirin (500 mg)
Study: 3323256
Drug: A-49816 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-49816 (0.5 to 20 mg)
Study: 31703936
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose (n=14)
Study: 31703936
Drug: 1/5th dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/5th dose (n=17)
Study: 31703936
Drug: 1/25th dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/25th dose (n=13)
Study: 21961441
Drug: Constraint therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint therapy plus electrical stimulation
Study: 30284506
Drug: Constraint therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint therapy
Study: 12640257
Drug: Irbesartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (angiotensin II type 1 receptor antagonist)
Study: 12640257
Drug: Atenolol (beta1-adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta1-adrenoceptor antagonist)
Study: 10460983
Drug: Luffa comp.-Heel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luffa comp.-Heel nasal spray (0.14 ml per application, 4 times per day)
Study: 10460983
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium spray (control)
Study: 10460983
Drug: Luffa comp.-Heel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luffa comp.-Heel nasal spray
Study: 10460983
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium spray
Study: 2491883
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of ifosfamide